About Us Resources Catalysts Start Free Trial →

Loading…

Day Trader Sniper provides algorithmic alerts and analysis, not trade advice.
Not financial advice. Trade at your own risk.

Quick Links

Download The App Resources Market Feed Stocks

Catalysts About Us Support Privacy policy Terms of use

©2026 Day Trader Sniper - all rights reserved

Home›Catalysts›Regulatory and Clinical

Catalyst Category

Regulatory and Clinical

Live feed of every catalyst classified under Regulatory and Clinical.

CATALYSTS IN FEED

168

AVG MAX MOVE

+116.8%

POSITIVE MOVES

100%

LARGEST MOVE

+664.1%

DSMB Efficacy Met FDA 510(k) Cleared FDA Approval FDA Fast Track FDA Meeting FDA Meeting Granted Generic Drug Approved Inconclusive Topline Results IND Cleared for Study IND Filed NDA Resubmission Orphan Drug Designation Positive Subgroup Data Positive Topline Results Primary Endpoint Met SPA Agreement Study Complete Trial Enrollment Complete

Range–

Showing 7 of 168

Regulatory and ClinicalNov 24, 2025 · 8:30am ET

GELSGelteq Limited Ordinary Shares

Gelteq Limited Announces Enhanced Bioavailability in Preclinical Results

Results show significant improvement over a leading on-market reference antihistamine product.

Be first on the next Regulatory and Clinical catalyst.

Day Trader Sniper alerts you the instant a setup like this triggers.

Download Free →

Max move

+47.2%

RVOL

9.9x

Max high

$1.36

Fuel

30m

Regulatory and ClinicalNov 24, 2025 · 8:30am ET

GELSGelteq Limited Ordinary Shares+47.2%

Gelteq Limited Announces Enhanced Bioavailability in Preclinical Results

RVOL

9.9x

Max high

$1.36

Fuel

30m

Regulatory and ClinicalNov 17, 2025 · 3:59pm ET

CANFCan-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares

Can-Fite BioPharma Announces 9-Year Survival with Complete Response in Namodenoson-Treated Patient

Patient treated for advanced liver cancer shows complete response.

Regulatory and ClinicalNov 17, 2025 · 3:59pm ET

CANFCan-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares+94.6%

Can-Fite BioPharma Announces 9-Year Survival with Complete Response in Namodenoson-Treated Patient

Regulatory and ClinicalNov 17, 2025 · 3:59pm ET

KZIAKazia Therapeutics Limited American Depositary Shares

Kazia Therapeutics Reports Initial Immune-Complete Response in TNBC Trial

Patient with Stage IV Triple-Negative Breast Cancer shows positive results.

Regulatory and ClinicalNov 17, 2025 · 3:59pm ET

KZIAKazia Therapeutics Limited American Depositary Shares+57.9%

Kazia Therapeutics Reports Initial Immune-Complete Response in TNBC Trial

Regulatory and ClinicalNov 17, 2025 · 10:22am ET

ANVSAnnovis Bio, Inc.

Annovis Bio Reports New Biomarker Data on Parkinson's Cognitive Decline

Company reveals findings on amyloid co-pathology and cognitive decline.

Regulatory and ClinicalNov 17, 2025 · 10:22am ET

ANVSAnnovis Bio, Inc.+68.8%

Annovis Bio Reports New Biomarker Data on Parkinson's Cognitive Decline

Regulatory and ClinicalNov 17, 2025 · 8:30am ET

GLMDGalmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Announced Enhanced GI Tumor Cell Killing with Aramchol, Stivarga, and Metformin Combination

Top-line results from oncology MoA studies revealed.

Regulatory and ClinicalNov 17, 2025 · 8:30am ET

GLMDGalmed Pharmaceuticals Ltd.+58.6%

Galmed Pharmaceuticals Ltd. Announced Enhanced GI Tumor Cell Killing with Aramchol, Stivarga, and Metformin Combination

Regulatory and ClinicalNov 17, 2025 · 8:00am ET

AMIXAutonomix Medical, Inc. Common Stock

Autonomix Medical Reports Positive Subgroup Results from First-in-Human Study

Results indicate potential benefits in mitigating severe pancreatic cancer pain.

Regulatory and ClinicalNov 17, 2025 · 8:00am ET

AMIXAutonomix Medical, Inc. Common Stock+101.3%

Autonomix Medical Reports Positive Subgroup Results from First-in-Human Study

Regulatory and ClinicalNov 12, 2025 · 7:59pm ET

CMNDClearmind Medicine Inc. Common Shares

Clearmind Medicine Receives Final Approval to Expand FDA-Regulated Trial for Alcohol Use Disorder

Expansion approved at Hadassah Medical Center.

Regulatory and ClinicalNov 12, 2025 · 7:59pm ET

CMNDClearmind Medicine Inc. Common Shares+109.0%

Clearmind Medicine Receives Final Approval to Expand FDA-Regulated Trial for Alcohol Use Disorder

1
…
10
11
12
…
24

RVOL

2.3x

Max high

$14.40

Fuel

3m

RVOL

9.5x

Max high

$10.25

Fuel

1h 23m

RVOL

5.3x

Max high

$4.00

Fuel

1h 36m

RVOL

6.7x

Max high

$13.20

Fuel

22m

RVOL

3.0x

Max high

$32.55

Fuel

1h 54m

RVOL

10.0x

Max high

$259.60

Fuel

4h 35m